人体免疫缺陷病毒 |
1
丙肝病毒
|
2
伪狂犬病毒
|
甲肝病毒 细小病毒 B19 3
|
参考文献
1 Cohn EJ et al . Preparation and properties of serum and plasma proteins ; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids . J Am Chem Soc 1946 ; 68:459 – 75 . 2 Kistler P , Nitschmann H . Large scale production of human plasma fractions . Eight years experience with the alcohol fractionation procedure of
|
Nitschmann , Kistler and Lergier . Vox Sang 1962 ; 7:414 – 24 . 3 European Medicines Agency 2011 . Guideline on the warning on transmissible agents in summary of product characteristics ( SmPCs ) and package leaflets for plasmaderived medicinal products . EMA / CHMP / BWP / 360642 / 2010 rev . 1 . 4 Dichtelmüller HO et al . Contribution to safety of immunoglobulin and albumin |
from virus partitioning and inactivation by cold ethanol fractionation : a data collection from Plasma Protein Therapeutics Association member companies . Transfusion 2011 ; 51:1412 – 30 . 5 Hilfenhaus J et al . A strategy for testing established human plasma protein manufacturing procedures for their ability to inactivate or eliminate human immunodeficiency virus . J Biol Stand 1987 ; 15:251 – 63 . |
6 Blümel J et al . Inactivation of parvovirus B19 during pasteurization of human serum albumin . Transfusion 2002 ; 42:1011 – 18 . 7 Von Hoegen I , Waller C . Safety of human albumin based on spontaneously reported serious adverse events . Crit Care Med 2001 ; 29:994 – 6 . 8 Vincent JL , Wilkes MM , Navickis RJ . Safety of human albumin – serious adverse events reported worldwide |
in 1998 – 2000 . Br J Anaesth 2003 ; 91:625 – 30 . |